| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H9N3O5S |
| Molecular Weight | 307.282 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)OC1=C(C=CC=C1)C(=O)NC2=NC=C(S2)[N+]([O-])=O
InChI
InChIKey=YQNQNVDNTFHQSW-UHFFFAOYSA-N
InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)
| Molecular Formula | C12H9N3O5S |
| Molecular Weight | 307.282 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Tizoxanide, the primary active metabolite of the FDA approved drug nitazoxanide, an anti-infective that has been approved for the treatment of diarrhea caused by Giardia lamblia. Tizoxanide, an active metabolite of nitazoxanide in humans, is also an antiparasitic drug of the thiazolide class. It has broad-spectrum antiparasitic and broad-spectrum antiviral properties. Besides, it has being found that Tizoxanide exhibits appreciable antagonist activity for both mGluR1 and mGluR5 (IC50 = 1.8 uM and 1.2 uM, respectively).
CNS Activity
Originator
Approval Year
Doses
AEs
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Sourcing
Sample Use Guides
Nitazoxanide treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum:
1-3 years old patients: 5 mL of Alinia for Oral Suspension (100 mg nitazoxanide) every 12 hourswith food for 3 days;
4-11 years old patients: 10 mL of Alinia for Oral Suspension (200 mg nitazoxanide) every 12 hours with food for 3 days;
≥12 years old patients: 1 Alinia Tablet (500 mg nitazoxanide) every 12 hours with food or
25 mL of Alinia for Oral Suspension
(500 mg nitazoxanide) every 12 hours
with food for 3 days
Route of Administration:
Oral
